
STORY BYTo those of us finally wise enough to view life clearly, it is a cruel evolutionary joke that we can no longer see life clearly. At the bare minimum, should not the length of our arms grow in direct proportion to our new short-sightedness?
Presbyopia is the formal term for imploring anyone under 30 to recite to us the total on our receipts, our prescription labels, our menus… It is the aging eyes’ diminished ability to focus on close-up tasks, which, in this era, involve everything except sleeping.
“This condition is the natural aging process of the eyes and usually begins about the age of 40,” says Richard W. Yee, M.D., professor of ophthalmology at The University of Texas Medical School at Houston and medical director of the Refractive and Cornea Unit at the Hermann Eye Center at Memorial Hermann Hospital.
So, as our generation loves to mutter: if they can put a man on the moon, can’t they restore our vision?
Yee is investigating a new surgical option to correct age-related near-vision loss as part of a Phase III Federal Drug Administration (FDA) clinical research study. If you are tired of fishing for your reading glasses, you may be interested.
“This trial is based on the theory of accommodation, which is the eye’s ability to naturally adjust its focus from distance to near objects,” explains Yee, who also holds the Joe M. Green, Jr., Endowed Chair in Ophthalmology at the medical school.
“As you age, presbyopia occurs as the crystalline lens grows larger, creating slack in the fibers of the eye that control its movement,” Yee explains. One of a variety of explanations offers that when the muscles try to contract to focus in, the fibers may be too loose to force the lens to change shape, he says.
The objective of the vision study is to evaluate the safety and effectiveness of the new surgical treatment. The devices are the scleral implants, and the scleral belt-loop creator.
The surgeon makes incisions at four points in the sclera or white of the eye around the lens. Then, scleral “belt loops” are fashioned at each point. Next, four plastic implants, each the size of a grain of rice, are inserted into the loops. The implants pull the ciliary muscles farther away from each other, decreasing the slack in the fibers. When the eyes move from a distant object to a close one, the fibers, once again, have the tension and strength to change the shape of the lens.
Patients can expect to have red eye for two to six weeks following the procedure. Short-term side effects may include pain, sensitivity to light, a feeling of "something in the eye," eyelid swelling, blurred vision, tearing, and pain around the eye when focusing on close objects.
As part of the Phase III trial, Yee has done a total of seven eyes to date, and over 50 are waiting to be screened. He will have done 120 surgeries by the time the trial ends next spring, Yee says.
In Phase II of the trial, in which Yee was not involved, 80 percent gained “three to six lines of near vision” which translates to being able to read the newspaper again with no other visual aid.
“When the findings from Phase II were submitted to the FDA in October, they were approved without revision. That was unusual and very exciting. This procedure has the possibility of being available to the public in about two years,” Yee says.
Working with presbyopia patients is not new to Yee, who did the first scleral expansion, its original name, at the Hermann Eye Center in the late 1990s. Representing the Center, he collaborated with Ronald A. Schachar, M.D., Ph.D., a Dallas eye surgeon, who developed the theory on which the clinical trial is based.
Schachar’s theorectical approach continues to be discussed. The American Academy of Ophthalmology and international vision researchers are reconsidering its understanding and definition of presbyopia.
Yee is looking for study participants who have presbyopia and are between 50 and 60 years old. If you have reading glasses, contacts or a bit of nearsightedness, farsightedness, or astigmatism, you may be eligible for the clinical trial. You are not a candidate if you wear distance glasses or have had a prior surgery on your eyes such as LASIK, RK or PRK or have a chronic eye disease.
If you are selected for surgery, you will be given a complete eye exam as well as a medical exam to determine your state of health. These preliminary activities are free. Following the procedure, you will be monitored for 24 to 30 months.
The name of the study is PresVIEWS Scleral Implant (PSI) for the Treatment of Presbyopia. Prospective participants can call 713-704-1839 or 713-704-0660. For more information, contact richard.w.yee@uth.tmc.edu.
UPDATED: 1-03-2006
Dr. Richard Yee is a clinical professor in the Department of Ophthalmology and Visual Science at the UT Medical School.
See Dr. Yee also at:
Special Instructions for Children Being Vaccinated Against Flu for the First Time:
Children 6 months up to 9 years of age getting a flu vaccine for the first time will need two doses of vaccine the first year they are vaccinated. If possible, the first dose should be given in September or as soon as vaccine becomes available. The second dose should be given 28 or more days after the first dose. The first dose "primes" the immune system; the second dose provides immune protection. Children who only get one dose but who need two doses can have reduced or no protection from a single dose of flu vaccine. Two doses are necessary to protect these children. If your child needs two doses, begin the process early, so that children are protected before influenza starts circulating in your community. Be sure to follow up to get your child a second dose if they need one. It usually takes about two weeks after the second dose for protection to begin.
Because flu viruses change every year, the vaccine is updated annually. So even if you or your children got a flu vaccine last year, you both still need to get a flu vaccine this season to remain protected. If October and November slip by, and you haven’t gotten your children or yourself vaccinated, get vaccinated in December or later.